CD25 Variant Engineering for Targeted Low-Dose IL-2 Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing IL-2 therapies induce severe toxicity and off-target effects due to non-specific activation of immune cells, limiting their therapeutic efficacy in treatments like adoptive immunotherapy.
Innovation Solution
Engineering cells to express a CD25 variant with increased affinity for IL-2 or an IL-2/IL-13 hybrid protein that binds to IL-13Rα2, allowing targeted IL-2 signaling and reducing the need for high doses, thereby minimizing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type IL-2 is administered at therapeutic doses, then immune cell activation and expansion is achieved, but severe toxicity and off-target effects occur
Solution Approach 1:
The patent applies local quality by creating CD25 protein variants with enhanced IL-2 binding affinity specifically in targeted cells. The CD25v1 and CD25v2 variants contain specific amino acid substitutions (e.g., D114N, Y120H, Q126R) that locally modify the binding interface to increase affinity for IL-2, allowing selective activation of engineered cells while sparing other immune cells from toxic effects
Solution Approach 2:
The patent implements parameter changes by modifying the binding affinity parameter of CD25 for IL-2. The variant proteins exhibit significantly enhanced binding affinity (lower Kd values) compared to wild-type CD25, enabling targeted cells to respond to lower concentrations of IL-2 and reducing the systemic dosage required for therapeutic effect
2Productivity
If high doses of IL-2 are used to achieve therapeutic effect, then cell expansion and activation is improved, but off-target activation of non-targeted cells increases
Solution Approach 1:
The patent enables selective activation by locally enhancing IL-2 binding affinity in targeted cells through CD25 variants. Engineered T cells expressing CD25v1 or CD25v2 can respond to low concentrations of IL-2, while other immune cells with wild-type CD25 require much higher concentrations, achieving selective expansion without off-target effects
Solution Approach 2:
The patent uses CD25 variant proteins as intermediaries that mediate selective IL-2 signaling. These variants act as high-affinity receptors that capture IL-2 preferentially in engineered cells, serving as a selective gateway that allows therapeutic IL-2 to activate only intended target cells while ignoring other immune cell populations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances IL-2 sensitivity in targeted cells while reducing systemic toxicity and off-target effects, enabling effective therapeutic applications with lower IL-2 doses.
Implementation Method 1
engineered proteins enhance the sensitivity of a cell to IL-2... The CD25 protein does not directly interact with the cytoplasmic signaling apparatus associated with the receptor complex, but rather it provides high affinity binding to IL-2
Implementation Method 2
an IL-2/IL-13 hybrid protein that binds to IL-13Rα2, allowing targeted IL-2 signaling
Data Source
AI summary
Engineered proteins, polynucleotides encoding such proteins, and methods of use thereof are provided, which engineered proteins enhance the sensitivity of a cell to IL-2.